---
schema_version: "secwatch.filing_event.v1"
accession: "0001672688-26-000066"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:13:39.358011+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Absci reports Q4 net loss $29.6M, advances ABS-201 trial, appoints new CMO

## Summary
- Dosed first three cohorts in SAD portion of Phase 1/2a HEADLINE trial for ABS-201; well-tolerated with favorable emerging safety.
- Net loss Q4 2025 $29.6M vs $29.0M prior year; full year net loss $115.2M vs $103.1M.
- Cash, equivalents, and marketable securities $144.3M as of Dec 31, 2025; sufficient to fund operations into first half 2028.
- Appointed Ransi Somaratne, M.D. (former Vertex SVP) as Chief Medical Officer to lead clinical strategy.
- Interim proof-of-concept data for ABS-201 expected H2 2026; Phase 2 endometriosis trial initiation planned Q4 2026.

## SEC filing metadata
- accession: 0001672688-26-000066
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000167268826000066/0001672688-26-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000167268826000066/absc-20260324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001672688-26-000066
- JSON: https://secwatch.observer/filing/0001672688-26-000066.json
- Plain text: https://secwatch.observer/filing/0001672688-26-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.